This product is a fixed-ratio blend of two growth-hormone-axis peptides, each with its own VialTalk monograph: Tesamorelin (a GHRH analogue) and Ipamorelin (a selective ghrelin-receptor agonist / GHRP). The research interest in combining them is a well-described physiological synergy — pairing a GHRH with a GHRP produces a larger growth-hormone pulse than either produces alone. This monograph summarises the two components, the dual-pathway rationale, the genuinely strong single-agent evidence for Tesamorelin, and the important fact that the combination itself has not been tested in controlled trials.
Chemical identity and structure.
The blend contains two distinct peptides at a fixed ratio. Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH). Ipamorelin is a selective pentapeptide ghrelin-receptor agonist. There is no single formula or molecular weight for the blend; each peptide retains its own identity and pharmacokinetics. See the individual VialTalk monographs for per-compound chemistry.
Mechanism of action.
The two components drive GH release through two different receptors, and that is the whole point. Tesamorelin activates GHRH receptors on anterior-pituitary somatotrophs, increasing the amplitude of GH pulses — the amount released per secretory event — without much changing pulse frequency. Ipamorelin activates the ghrelin receptor, increasing pulse frequency, and is "selective" in the sense that it raises GH with minimal effect on cortisol, prolactin, or hunger (a contrast with older GHRPs). Co-activating both pathways produces a synergistic GH pulse: the endocrinology literature reports GH secretion several-fold higher (commonly cited as roughly 2–5×) when a GHRH analogue and a ghrelin agonist are given together than with either alone.
Research applications and the evidence base.
The two components are not equally evidenced, and the blend is less evidenced than either. Tesamorelin has robust human clinical data — it is studied (and approved in the HIV-associated lipodystrophy setting) for reducing visceral adipose tissue, with reported visceral-fat reductions in the mid-teens percent and modest lean-mass gains. Ipamorelin's evidence is largely preclinical and early-stage. Critically, there are no published controlled trials of Tesamorelin and Ipamorelin administered together as a fixed blend; every combination figure is extrapolated from the single-agent data plus the general GHRH/GHRP synergy literature. Present the combination as mechanistically motivated, not as clinically validated.
No human clinical trial has established administration parameters for the Tesamorelin + Ipamorelin blend; VialTalk does
not provide community-sourced dosing.
Storage and handling.
Store the lyophilized blend frozen (−20 °C). As with any blend, default to the more conservative stability window of the two components.
Quality and COA considerations.
A meaningful COA should confirm identity by mass spectrometry for both peptides, report purity by HPLC, and report the ratio of Tesamorelin to Ipamorelin rather than a single total mass. Endotoxin should be reported for injection or tissue-contact models.
Research-use note: This monograph is an educational summary of the published research literature for the Tesamorelin + Ipamorelin blend and its individual components. It is for laboratory and research use only. Tesamorelin has substantial single-agent human data; the fixed combination does not; and nothing here is medical advice.
